GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » Payments of Debt

GYRE (Gyre Therapeutics) Payments of Debt : $0.0 Mil (TTM As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics Payments of Debt?

Gyre Therapeutics's Payments of Debt for the three months ended in Dec. 2024 was $0.0 Mil.

Gyre Therapeutics's Payments of Debt for the trailing twelve months (TTM) ended in Dec. 2024 was $0.0 Mil.

Gyre Therapeutics Payments of Debt Historical Data

The historical data trend for Gyre Therapeutics's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics Payments of Debt Chart

Gyre Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Payments of Debt
-6.70 -0.47 - -

Gyre Therapeutics Quarterly Data
Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Gyre Therapeutics Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gyre Therapeutics Payments of Debt Related Terms

Thank you for viewing the detailed overview of Gyre Therapeutics's Payments of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Gyre Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » Payments of Debt
Comparable Companies
ZYME OCS ELVN AVBP REPL ABCL SPRY COGT OCUL XNCR VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
L9S:Germany
Address
12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130
Website
https://www.gyretx.com
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.